University Of California Los Angeles

The addition of bemarituzumab to modified FOLFOX6 benefited patients with advanced gastric and gastroesophageal junction cancer with FGFR2b overexpression, according to data presented at Gastrointestinal Cancers Symposium.

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.

Two studies published in JAMA of mechanical thrombectomy alone vs. mechanical thrombectomy plus IV thrombolysis in patients with acute ischemic stroke contradicted each other.

Two behavioral intervention programs appeared to effectively reduce depression symptoms among a cohort of young breast cancer survivors, according to study results presented at the virtual San Antonio Breast Cancer Symposium.

Women with metastatic triple-negative breast cancer benefited from sacituzumab govitecan irrespective of their Trop-2 expression level and BRCA1/BRCA2 mutation status, according to data from the phase 3 ASCENT study.

The FDA today approved Gallium 68 PSMA-11 as the first drug for PET imaging of prostate-specific membrane antigen-positive lesions in men with prostate cancer, according a press release from the agency.

More than 40% of patients with lymph node involvement at breast cancer diagnosis could be spared lymph node surgery, according to study results published in Annals of Surgical Oncology.

Marijuana use for recreational and medicinal purposes has increased during the past several years, along with a rise in vaping nicotine products for recreational use and smoking cessation.

An artificial intelligence voice analysis tool can help diagnose COVID-19 in asymptomatic patients, according to its manufacturer, Vocalis Health.

Among female veterans, PTSD was an independent predictor of future ischemic heart disease, according to findings presented at the virtual American Heart Association Scientific Sessions.